CoChat

Health‐economic analysis of real‐time continuous glucose monitoring in people with Type 1 diabetes

Roze, S., Saunders, R., Brandt, A.‐S., de Portu, S., Papo, N. L., Jendle, J. · 2015 · Diabetic Medicine
Cited by 40

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Aim: To evaluate the clinical benefits and cost‐effectiveness of the sensor‐augmented pump compared with self–monitoring of plasma glucose plus continuous subcutaneous insulin infusion in people with Type 1 diabetes. Methods: The CORE Diabetes Model was used to simulate disease progression in a cohort of people with baseline characteristics taken from a published meta‐analysis. Direct and indirect costs for 2010–2011 were calculated from a societal payer perspective, with cost‐effectiveness calculated over the patient's lifetime. Discount rates of 3% per annum were applied to the costs and the clinical outcomes. Results: Use of the sensor‐augmented pump was associated with an increase in mean discounted, quality–adjusted life expectancy of 0.76 quality–adjusted life years compared with continuous subcutaneous insulin infusion (13.05 ± 0.12 quality–adjusted life years vs 12.29 ± 0.12 quality–adjusted life years, respectively). Undiscounted life expectancy increased by 1.03 years for the sensor‐augmented pump compared with continuous subcutaneous insulin infusion. In addition, the onset of complications was delayed (by a mean of 1.15 years) with use of the sensor‐augmented pump. This analysis resulted in an incremental cost–effectiveness ratio of 367,571 SEK per quality–adjusted life year gained with the sensor‐augmented pump. The additional treatment costs related to the use of the sensor‐augmented pump were partially offset by the savings attributable to the reduction in diabetes‐related complications and the lower frequency of self‐monitoring of plasma glucose. Conclusions: Analysis using the CORE Diabetes Model showed that improvements in glycaemic control associated with sensor‐augmented pump use led to a reduced incidence of diabetes‐related complications and a longer life expectancy. Use of the sensor‐augmented pump was associated with an incremental cost–effectiveness ratio of 367,571 SEK per quality–adjusted life year gained, which is likely to represent good value for money in the treatment of Type 1 diabetes in Sweden.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dme.12661

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 40

Metadata

Authors
Roze, S., Saunders, R., Brandt, A. ‐., de Portu, S., Papo, N. L., & Jendle, J.
Venue
Diabetic Medicine
Publisher
Wiley
Published
2015-01-06
Volume
32
Issue
5
Pages
618-626
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
OpenAlex
W2080320583
Cited by
40
References
7
FWCI
5.03
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.